Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

A new locus for dominant drusen and macular degeneration maps to chromosome 6q14.

Kniazeva M, Traboulsi EI, Yu Z, Stefko ST, Gorin MB, Shugart YY, O'Connell JR, Blaschak CJ, Cutting G, Han M, Zhang K.

Am J Ophthalmol. 2000 Aug;130(2):197-202.

2.

Mutation analysis of GABRR1 and GABRR2 in autosomal recessive retinitis pigmentosa.

Marcos I, Ruiz A, Blaschak CJ, Borrego S, Cutting GR, Antinolo G.

J Med Genet. 2000 Jun;37(6):E5. No abstract available.

3.

Mutation of human mu opioid receptor extracellular "disulfide cysteine" residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane.

Zhang P, Johnson PS, Zöllner C, Wang W, Wang Z, Montes AE, Seidleck BK, Blaschak CJ, Surratt CK.

Brain Res Mol Brain Res. 1999 Oct 1;72(2):195-204.

PMID:
10529478
4.

Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity.

Spivak CE, Beglan CL, Seidleck BK, Hirshbein LD, Blaschak CJ, Uhl GR, Surratt CK.

Mol Pharmacol. 1997 Dec;52(6):983-92.

PMID:
9415708
5.

-mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity.

Surratt CK, Johnson PS, Moriwaki A, Seidleck BK, Blaschak CJ, Wang JB, Uhl GR.

J Biol Chem. 1994 Aug 12;269(32):20548-53.

Supplemental Content

Loading ...
Support Center